Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome

Myeloid Leukemia ◽

Phase 2 ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Results of a phase 2, multicenter, single‐arm, open‐label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia

Pediatric Blood & Cancer ◽

10.1002/pbc.28946 ◽

2021 ◽

Author(s):

Maureen M. O'Brien ◽

Todd A. Alonzo ◽

Todd M. Cooper ◽

John E. Levine ◽

Patrick A. Brown ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Pediatric Patients ◽

Phase 2 ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Effect of rhG-CSF Combined with Decitabine Prophylaxis on Relapse in High-Risk Acute Myeloid Leukemia Patients after Hematopoietic Stem Cell Transplantation: An Open-Label, Multicenter, Randomized, Controlled, Phase 2 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3487801 ◽

2019 ◽

Author(s):

Lei Gao ◽

Yanqi Zhang ◽

Sanbin Wang ◽

Peiyan Kong ◽

Yi Su ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Stem Cell ◽

High Risk ◽

Myeloid Leukemia ◽

Phase 2 ◽

Open Label ◽

Hematopoietic Stem ◽

Randomized Controlled ◽

Phase 2 Trial ◽

Effect of rhG-CSF Combined with Decitabine Prophylaxis on Relapse in High-Risk Acute Myeloid Leukemia Patients after Hematopoietic Stem Cell Transplantation: An Open-Label, Multicenter, Randomized, Controlled, Phase 2 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3487826 ◽

2019 ◽

Author(s):

Lei Gao ◽

Yanqi Zhang ◽

Sanbin Wang ◽

Peiyan Kong ◽

Yi Su ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Stem Cell ◽

High Risk ◽

Myeloid Leukemia ◽

Phase 2 ◽

Open Label ◽

Hematopoietic Stem ◽

Randomized Controlled ◽

Phase 2 Trial ◽

Dose-enhanced combined priming regimens for refractory acute myeloid leukemia and middle-and-high-risk myelodysplastic syndrome: a single-center, retrospective cohort study

OncoTargets and Therapy ◽

10.2147/ott.s96427 ◽

2016 ◽

pp. 3661 ◽

Cited By ~ 3

Author(s):

Xiaorong Ma ◽

Jin Wang ◽

Yan Xu ◽

Wanggang Zhang ◽

Jie Liu ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Cohort Study ◽

High Risk ◽

Retrospective Cohort Study ◽

Myeloid Leukemia ◽

Retrospective Cohort ◽

Single Center ◽

A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome

American Journal of Hematology ◽

10.1002/ajh.25958 ◽

2020 ◽

Vol 95 (12) ◽

pp. 1457-1465

Author(s):

Caner Saygin ◽

Karilyn Larkin ◽

James S. Blachly ◽

Shelley Orwick ◽

Apollinaire Ngankeu ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Phase I ◽

Myeloid Leukemia ◽

Phase I Study ◽

A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Case Medical Research ◽

10.31525/ct1-nct04243785 ◽

2020 ◽

Author(s):

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Myeloid Leukemia ◽

Phase III randomized, open-label study comparing the efficacy and safety of AG-221 vs conventional care regimens (CCR) in older patients with advanced acute myeloid leukemia (AML) with isocitrate dehydrogenase (IDH)-2 mutations in relapse or refractory to multiple prior treatments: the IDHENTIFY trial.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps7074 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS7074-TPS7074 ◽

Cited By ~ 6

Author(s):

Martin S. Tallman ◽

Robert D. Knight ◽

Axel G. Glasmacher ◽

Hartmut Dohner ◽

Keyword(s):

Acute Myeloid Leukemia ◽

Older Patients ◽

Myeloid Leukemia ◽

Conventional Care ◽

Phase Iii ◽

Efficacy And Safety ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

A phase II open-label study of aprepitant as anti-emetic prophylaxis in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy

Supportive Care in Cancer ◽

10.1007/s00520-018-4515-4 ◽

2018 ◽

Vol 27 (6) ◽

pp. 2295-2300 ◽

Cited By ~ 2

Author(s):

Joseph M. Brandwein ◽

Jack T. Seki ◽

Eshetu G. Atenafu ◽

Amr Rostom ◽

Andrzej Lutynski ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Induction Chemotherapy ◽

Phase Ii ◽

Myeloid Leukemia ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study

International Journal of Hematology ◽

10.1007/s12185-019-02727-6 ◽

2019 ◽

Vol 110 (6) ◽

pp. 665-674 ◽

Cited By ~ 3

Author(s):

Takeshi Takahashi ◽

Kensuke Usuki ◽

Kosei Matsue ◽

Hitoshi Ohno ◽

Toru Sakura ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Japanese Patients ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase ◽

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Case Medical Research ◽

10.31525/ct1-nct04047641 ◽

2019 ◽

Author(s):

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Myeloid Leukemia ◽

Newly Diagnosed ◽